SIREN : 341419109
ERGYPHARM is a French company founded 38 years ago, specialized in the sector Activités des sociétés holding. Based in NIEDERHAUSBERGEN (67207), this company of category PME shows in 2019 a net income positive of 74 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2019 | 2017 | 2015 |
|---|---|---|---|
| Revenue | N/C | N/C | N/C |
| Net income | 74 485 € | 99 484 € | 33 693 € |
| EBITDA | N/C | N/C | N/C |
| Net margin | N/C | N/C | N/C |
In 2019, ERGYPHARM generates positive net income of 74 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2015-2019: 34 k€ -> 74 k€.
74 485 €
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 96%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
0.262%
95.944%
49.6%
In 2019, the debt ratio of ERGYPHARM (0.26) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2019, the financial autonomy of ERGYPHARM (95.9%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
The liquidity ratio (= Current assets / Current liabilities) stands at 1645.29. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
1645.293
In 2019, the liquidity ratio of ERGYPHARM (1645.29) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 322 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 657 days. Excellent situation: suppliers finance 335 days of the operating cycle (retail model).
0 €
322 j
657 j
0 j
Based on 72 transactions of similar company sales
in 2019,
the value of ERGYPHARM is estimated at
565 932 €
(range 98 062€ - 1 170 913€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 72 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare ERGYPHARM with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of ERGYPHARM is not publicly disclosed (confidential accounts filed with INPI).
Yes, ERGYPHARM generated a net profit of 74 k€ in 2019.
The headquarters of ERGYPHARM is located in NIEDERHAUSBERGEN (67207), in the department Bas-Rhin.
The tax return of ERGYPHARM is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
ERGYPHARM operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.